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Summary
The first 6 residues of the biosurfactant lipopeptido-
lactone arthrofactin have the D configuration, yet
none of the 11 modules of the nonribosomal peptide
synthetase assembly line have epimerization do-
mains. We show that the two-module ArfA subunit
and the first module of the ArfB subunit, which act
in tandem to produce the N-acyl-D-Leu1-D-Asp2-D-
Thr3-S-protein intermediate, activate the L amino
acids and epimerize them as the aminoacyl-S-pante-
theinyl T domain intermediates before the next down-
stream condensation. The condensation (C) domains
are shown to have DCL chirality in peptide bond forma-
tion. The upstream aminoacyl/peptidyl moiety is
epimerized before condensation only when the con-
densation domains are simultaneously presented with
the L-aminoacyl-S-pantetheinyl acceptor. These DCL
catalysts are dual function condensation/epimeriza-
tion domains that can be predicted by bioinformatics
analysis to be responsible for incorporation of all D
residues in arthrofactin and of D residues in syringo-
mycin, syringopeptin, and ramoplanin synthetases.
Introduction
Nonribosomal peptide synthetases (NRPSs) are large,
multifunctional enzymes that synthesize a vast array of
biologically relevant natural products [1–4]. NRPS sys-
tems are organized into an assembly line of distinct
modules, the order of which is often colinear with the
primary sequence of the final peptide product [5].
Each module is composed of a set of semiautonomous
domains, each responsible for carrying out a specific
catalytic or carrier function [6]. The core domains within
a module include the adenylation (A) domain, which is
responsible for substrate recognition and activation as
an aminoacyl-O-AMP at the expense of ATP [7], and
its cognate peptidyl carrier protein (PCP) or thiolation
(T) domain, to which the substrate is covalently tethered
as a thioester to a 40-phosphopantetheine (Ppant) moi-
ety appended posttranslationally to an invariant serine
in a highly conserved region of the T domain [8, 9]. In ad-
dition to the A and T domains that comprise the basic
units of an initiation module, elongation modules con-
tain condensation (C) domains that catalyze peptide
bond formation by facilitating attack of the nucleophilic
free amine of the downstream aminoacyl-S-Ppant on
the upstream nascent peptidyl-S-Ppant thioester [10,
*Correspondence: christopher_walsh@hms.harvard.edu11]. Thus, the growing peptidyl chain is transferred to
downstream modules in an elongating cascade that cul-
minates in the release of the final product through either
hydrolysis or cyclization [1–4].
In addition to functionality for monomer recognition,
activation, loading, and coupling, NRPSs often contain
auxiliary domains that can modify the tethered building
blocks, thus contributing significantly to the structural
diversity of nonribosomal peptide products [12]. One
such example is the epimerization (E) domain. A hall-
mark of NRPS products is that they may contain
nonproteinogenic D amino acid residues. The D config-
urations may play a functional role by slowing the deg-
radation of NRPS products by naturally L-specific
proteases or may serve structural roles by properly ori-
enting side chain conformers for subsequent process-
ing steps [13–16], e.g., in vancomycin. The inclusion of
D amino acids increases the variety of nonribosomal
peptides produced and is important for bioactivity.
Although one rare mechanism for the incorporation of
D amino acids is their direct selection and activation by
the A domain [17], D amino acids most often arise in situ
by the action of embedded epimerization domains after
the L amino acid has been activated by the A domain
and covalently tethered to its respective T domain [3,
15, 18]. Epimerization domains are usually found di-
rectly after the T domain loaded with the amino acid
to be epimerized. This is the case for the NRPSs of
gramicidin S, tyrocidine, bacitracin, vancomycin, ceph-
alosporin, and penicillin [14, 19], which are produced by
the gram-positive bacteria Bacillus brevis, Bacillus li-
cheniformis, and Amycolatopsis orientalis and the fungi
Cephalosporium acremonium and Penicillium chryso-
genum, respectively. In one case, epimerization do-
mains can be found between the A and T domains for
the amino acid to be epimerized, a strategy employed
by pyochelin synthetase from the gram-negative bacte-
rium Pseudomonas aeruginosa [20].
The nonribosomal peptide arthrofactin produced by
Pseudomonas sp. MIS38, an extremely potent biosur-
factant [21], has become the founding member of a
new class of cyclic lipoundecapeptides isolated from
Pseudomonas spp. These molecules—including amphi-
sin, lokisin, and tensin, which possess antifungal prop-
erties, and pholipeptin, which possesses enzyme
inhibitory activity against phospholipase C—all contain
a b-hydroxydecanoyl moiety and 11 amino acids that
differ at four positions between the five molecules (Fig-
ure 1A). Arthrofactin is necessary for proper biofilm for-
mation and contributes highly to swarming motility, two
processes which are of critical importance in bacterial
spread and survival [22].
Sequencing of the arthrofactin gene cluster revealed
that it encodes a three protein, 11 module NRPS. The
three enzymes, termed ArfA, ArfB, and ArfC contain
two, four, and five functional modules, respectively,
which adhere to the colinearity rule (Figure 1B) [22]. Al-
though this NRPS follows the canonical C-A-T rule for
module organization, there is a discrepancy between
the encoded genes and the structure of the final
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the lipopeptide product are D amino acids, yet there
are no epimerization domains in any of the 3 compo-
nents of the NRPS. In other NRPS systems that synthe-
size cyclic lipopeptides, such as surfactin [23] and
fengycin [24] from Bacillus subtilis, there is a corre-
sponding E domain for every D amino acid incorporated
into the final nonribosomal peptide product. Further-
more, unlike the biosynthetic gene cluster for cyclo-
sporine synthetase that encodes a dedicated alanine
racemase to provide substrate for the D-Ala-specific A
domain in the first module [25], the arthrofactin gene
cluster does not encode an external racemase, and
the first A domain is L-Leu specific, whereas the final
product contains D-Leu [22].
Figure 1. Arthrofactin Structure and NRPS Organization
(A) Structure of arthrofactin and differences between lipoundeca-
peptide family members. HDA signifies 3-hydroxydecanoyl acid.
(B) Organization of arthrofactin synthetase.
(C) SDS-7.5% PAGE of the Arf constructs with molecular weight
standards.Sequence alignment of arthrofactin synthetase with
other known NRPSs reveals that it shares the greatest
homology with two other lipopeptide synthetases from
Pseudomonas syringae, the products of which are the
phytotoxins syringomycin and syringopeptin. Interest-
ingly, both syringomycin and syringopeptin also contain
D amino acids without any epimerization domains pres-
ent in their respective NRPS modules [26, 27].
In this study, we reconstitute the activity of the first
three modules of arthrofactin synthetase in vitro and
demonstrate that the epimerization activity is cryptically
embedded within the synthetase itself. Using sequence
alignment from four NRPS systems that produce pepti-
des containing D amino acids in the absence of epime-
rization domains, we attribute epimerization activity to
a novel subtype of C domain with dual catalytic activity
for both epimerization and condensation.
Results
Cloning and Expression of Arf Constructs
Several constructs derived from the first two NRPS com-
ponents of arthrofactin synthetase, namely, full-length
ArfA-C1A1T1C2A2T2, ArfA-C1A1T1, ArfA-C2A2T2, ArfA-
A2T2, ArfB-C3, ArfB-C3A3T3, and the T2 mutant ArfA-
C1A1T1C2A2T2 S2079A, were amplified from a l5 clone
of the arthrofactin gene cluster from Pseudomonas sp.
MIS38 [22] and were cloned into either N-terminal or C-
terminal His-tagged vectors. Sequencing of pArfA-
C1A1T1 and pArfA-C1A1T1C2A2T2 (three independent
PCR amplifications for each plasmid) revealed a single
nucleotide change of cytosine 581 to adenine, which al-
ters Ala194 in the GenBank sequence (accession number
AB107223) to Asp. Sequencing of pArfB-C3A3T3 (three
independent PCR amplifications) revealed two nucleo-
tide changes from the deposited sequence: adenine
2648 to guanine, which alters His893 to Arg, and adenine
2994 to guanine, which is silent at Leu998. Prevalence of
these mutations throughout all clones implies that the
GenBank sequence is likely to be incorrect at these three
positions. Expression in E. coli at reduced temperature,
either 25ºC or 15ºC, with 0.1 mM IPTG induction, yielded
4–6 mg/L protein for all constructs. Using nickel-affinity
chromatography and gel filtration in tandem, all proteins
were purified to homogeneity (Figure 1C).
ATP-PPi Exchange Assays to Evaluate A Domain
Stereoselectivity
In order to determine whether cryptic epimerase activity
exists within one or more domains of arthrofactin syn-
thetase, it was necessary to establish the stereospeci-
ficity of the A domains activating the residues that
were assigned D chirality in the final arthrofactin mole-
cule. Previously, only the first A domains of ArfA (A1)
and ArfC (A7), responsible for incorporating D-Leu1 and
L-Leu7, were purified and shown to possess specificity
for activating L-Leu. All other A domains were assigned
predicted substrate specificity based on sequence ho-
mology to other known A domains and by using the co-
linearity rule for NRPSs [22]. Furthermore, no kinetic
studies had been performed on any of the A domains
in arthrofactin synthetase. Employing a standard ATP-
PPi exchange assay, kobs at 1 mM substrate and Michae-
lis-Menten kinetic parameters were determined for the
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which activates amino acids that attain the D configura-
tion in the final arthrofactin product.
The first A domain of ArfA (by using ArfA-C1A1T1) was
shown to activate the following amino acids (kobs at 1
mM): L-Leu (156 min21), D-Leu (66 min21), L-Ile (12.8
min21), L-Val (1.6 min21), and L-Ala (0.13 min21). The
second A domain of ArfA (by using ArfA-C2A2T2) was
shown to activate the following amino acids (kobs at 1
mM): L-Asp (143 min21), D-Asp (2.0 min21), L-Asn (8.9
min21), and L-Glu (2.2 min21). No activity was detected
with L-Ile and L-Ala. The second A domain of ArfA was
also tested by using the ArfA-A2T2 construct, and the
following kobs values at 1 mM were obtained: L-Asp
(41 min21) and D-Asp (0.18 min21). The substrate prefer-
ence of the ArfA-C2A2T2 and ArfA-A2T2 are in agreement
in terms of which substrate isomer is preferentially ad-
enylated, but the kobs values for the ArfA-A2T2 construct
are 4- to 10-fold lower than that of the ArfA-C2A2T2 con-
struct. This is presumed to be a consequence of trun-
cating the module and exposing the N-terminal portion
of the A domain. Therefore, because it was shown that
the ArfA-A2T2 construct is functional, further kinetics
were performed only using ArfA-C2A2T2. Interestingly,
A2 from ArfA, which shows 70% homology to A domains
that activate L-Ile and only 60% homology to A domains
that activate L-Asp [22], showed no activity toward ad-
enylation of L-Ile. The A3 domain of ArfB (by using ArfB-
C3A3T3) was shown to activate the following amino
acids (kobs at 1 mM): L-Thr (73 min
21), D-Thr (2.6
min21), L-Ser (8.6 min21), and L-Val (0.15 min21). No ac-
tivity was detected with L-Ala.
From the initial kobs obtained, it was evident that, in all
three cases, the A domains showed specificity for acti-
vating the L amino acid rather than the D amino acid.
This finding was confirmed by determining Michaelis-
Menten parameters for the L and D isomers of the cog-
nate amino acid as well as the noncognate amino acid
showing the highest kobs at 1 mM substrate (Table 1).
The kcat was highest for the cognate L amino acid in
all three A domains tested, and, similarly, the Km was
lowest for the cognate L amino acid in all cases. The
specificity (kcat/Km) was highest for the cognate L amino
acid over any other substrate in all three cases. In fact,
successive A domains within the synthetase appear to
become more specific for activation of the L amino
acid versus the D amino acid. ArfA-A1 has a 10-fold
Table 1. Michaelis-Menten Kinetics of the First Three A Domains
of Arthrofactin Synthetase
Construct
Amino
Acid Km (mM) kcat (min
21)
kcat/Km
(mM21min21)
ArfA-C1A1T1 L-Leu 0.07 (0.02) 283 (10) 3880 (1200)
D-Leu 0.30 (0.08) 122 (6) 405 (130)
L-Ile 6.5 (0.7) 42 (2) 6.5 (1.0)
ArfA-C2A2T2 L-Asp 1.6 (0.2) 320 (10) 200 (30)
D-Asp >17 CNBDa 0.41 (0.01)
L-Asn 1.5 (0.3) 5.6 (0.3) 4 (1)
ArfB-C3A3T3 L-Thr 0.76 (0.09) 133 (4) 175 (25)
D-Thr >17 CNBDa 0.17 (0.07)
L-Ser >17 CNBDa 1.8 (0.1)
Values in parentheses represent standard errors.
a Could not be determined due to high Km.higher specificity for L-Leu over D-Leu, ArfA-A2 has
a 485-fold higher specificity for L-Asp over D-Asp, and
ArfB-A3 has a 1030-fold higher specificity for L-Thr
over D-Thr. Taken together, these data suggest that
the A domains are in fact specific for activation of L
amino acids and that epimerizations must occur at sub-
sequent stages of nonribosomal peptide synthesis.
Phosphopantetheinylation and Covalent Amino
Acid Loading
Before assaying for intrinsic epimerization activity, it
was necessary to determine whether the constructs
were competent for covalent thioesterification of the
amino acid substrate to the target T domain. Reaction
with CoASH and the phosphopantetheinyl transferase
Sfp [28, 29] converted the purified apo proteins to post-
translationally modified holo forms. Maximal covalent
incorporation of 14C-labeled substrate onto the phos-
phopantetheinyl prosthetic group on the T domains
was achieved within 1 min of initiating the adenylation
reaction for all constructs, as measured by TCA precip-
itation followed by liquid scintillation counting or autora-
diography of aminoacylated protein (data not shown).
With the general catalytic activity of the A domains
and reconstitution of the holo forms of the T domains
in all constructs verified, condensation and epimeriza-
tion were then assayed.
Leu1 Epimerization and Condensation with L-Asp2
Utilizing the full-length ArfA construct, ArfA-
C1A1T1C2A2T2, autoaminoacylated with both L-Leu (T1)
and L-Asp (T2), epimerization of L-Leu to D-Leu and
condensation of both L-Leu and D-Leu to L-Asp cata-
lyzed by C2 was observed (Figure 2A). The data in Figure
2A are from a 10 min incubation with 0.12 nmoles of en-
zyme active sites. At most, a stoichiometric equilibra-
tion of L- and D-Leu and subsequent condensation
with L-Asp will occur on the aminoacyl-S-pantetheinyl
proteins. To enable detection, L-[14C]Leu or L-[14C]Asp
were used, and the amino acids were released by thio-
esterase treatment [30] prior to chiral TLC analysis.
When L-Leu was radiolabeled, four spots were ob-
served on the TLC corresponding to D-Leu, L-Leu, D-
Leu-L-Asp, and L-Leu-L-Asp, in ascending order (Figure
2A). When L-Asp was radiolabeled, three spots were
observed on the TLC corresponding to L-Asp, D-Leu-
L-Asp, and L-Leu-L-Asp, in ascending order (Figure
2A). It should be noted that the diffuse spot attributed
to D-Leu-L-Asp is thought to result from different pro-
tonation states of the L-Asp moiety on the dipeptide
and was observed intermittently in both reactions and
standards. The difficulty in controlling the Asp proton-
ation state made subsequent analysis of the Asp2 epi-
merization by TLC unsuccessful and prompted
a change to HPLC evaluation.
In contrast, when full-length ArfA was loaded with
only L-Leu, epimerization was not observed, and obvi-
ously no dipeptide was formed (Figure 2A). Incubation
of the first module, ArfA-C1A1T1, with either only L-Leu
or both L-Leu and L-Asp also did not yield any epimeri-
zation (Figure 2A). This result implies that epimerization
requires an aminoacylated downstream T domain that is
primed for peptide bond formation.
Chemistry & Biology
1192Figure 2. Epimerase Activity Embedded within Arthrofactin Synthetase
(A) Chiral radioTLC images depicting various reactions performed by using L-[14C]Leu loaded onto T1 of ArfA or L-[
14C]Asp loaded onto T2 of
ArfA.
(B) Chiral radioHPLC traces depicting various reactions performed by using L-[14C]Asp loaded onto T2 of ArfA.
(C) Chiral radioHPLC traces depicting various reactions performed by using L-[14C]Asp loaded onto T2 of ArfA or L-[
14C]Thr loaded onto T3 of
ArfB.
(D) RadioHPLC trace of a 70/30 mixture of N-acyl-L-Leu-CoA/CoASH loaded onto ArfA-C1A1T1C2A2T2 and reacted after covalent aminoacy-
lation of L-[14C]Asp onto T2 (Reaction). Standard 1 was monitored by
14C radioactive counts; Standard 2 and Standard 3 were monitored
at 220 nm.
Detailed reaction conditions for (A), (B), (C), and (D) are described in Experimental Procedures.In order to demonstrate that L-Asp must be covalently
loaded on the downstream T domain and not simply in
solution, and to test whether the cryptic epimerase ac-
tivity could be triggered with free amino acid rather
than a downstream aminoacyl-T domain, a full-length
ArfA T2 knockout construct was created. This construct
is ArfA-C1A1T1C2A2T2 S2079A, in which the conserved
phosphopantetheinylated serine in the T2 domain was
mutated to alanine, thus irreversibly confining the sec-
ond module to the apo form. Upon incubation with
either L-Leu alone or both L-Leu and L-Asp, no epime-
rization and no condensation were observed (Figure
2A). This finding supports the notion that the second
module must be loaded with the downstream aminoacyl
thioester for the first amino acid to be epimerized.
Asp2 Epimerization and Condensation with L-Thr3
Similar to the results observed for the Leu1 epimeriza-
tion reaction, Asp2 loaded onto T2 of ArfA was only epi-
merized when it interacted with ArfB-C3A3T3 loaded
with L-Thr. When ArfA-C2A2T2 or ArfA-A2T2 was cova-
lently loaded with L-Asp in the presence or absence of
L-Thr, no epimerization to D-Asp was observed in the
chiral radioHPLC traces (Figure 2B). Correspondingly,
interaction of L-Asp-loaded ArfA-C2A2T2 or ArfA-A2T2
with ArfB-C3 in the presence or absence of L-Thr or
ArfB-C3A3T3 in the absence of L-Thr also yielded noepimerization to D-Asp (Figure 2B). However, when
ArfA-C2A2T2 or ArfA-A2T2 loaded with L-Asp interacted
with ArfB-C3A3T3 loaded with L-Thr, epimerization to
D-Asp was observed, and only the D-Asp-L-Thr dipep-
tide was formed (Figure 2C).
Formation of only the D-Asp-L-Thr dipeptide was con-
firmed by repeating the experiments in the reciprocal
manner, with L-Thr radiolabeled instead of L-Asp radio-
labeled (Figure 2C). These results support a mechanism
in which epimerization precedes condensation to a
downstream amino acid but only occurs if the down-
stream amino acid is loaded onto its T domain and
primed for condensation. It strongly suggests that ArfB
C3 is a
DCL catalyst.
The b-Hydroxyacyl Moiety N-Acylated to Leu1
Confers Specificity for D-Leu-L-Asp Condensation
As described above, epimerization of the upstream
amino acid for the first two modules of arthrofactin syn-
thetase requires that the downstream amino acid be
loaded onto its T domain and be presented simulta-
neously to the upstream C domain. However, a differ-
ence was observed in the condensation products
produced by the two condensation domains involved
in the process. Whereas the ArfB C3 domain formed
only the D-Asp-L-Thr dipeptide product, the ArfA C2 do-
main formed both the L-Leu-L-Asp and D-Leu-L-Asp
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N-acyl group, presumed to be condensed with Leu1 at
the initial stages of arthrofactin formation, could en-
hance specificity for DCL catalysis by the ArfA C2
domain.
Initially, the reaction was attempted in trans with the
ArfA-C1A1T1 and ArfA-C2A2T2 constructs rather than
the full-length ArfA-C1A1T1C2A2T2 construct because
Sfp is indiscriminate as to which T domain it phospho-
pantetheinylates. However, the in trans reaction did
not yield any epimerization or condensation products
when tested with the positive control of Sfp priming
with CoASH followed by loading of L-Leu and L-Asp.
Therefore, the reaction was performed with the
full-length ArfA-C1A1T1C2A2T2 construct and a 70/30
mixture of 3-hydroxybutyryl-L-Leu-CoA (N-acyl-L-Leu-
CoA) and CoASH, respectively. Skewing of the mixture
away from 50/50 was done because Sfp more readily
accepts free CoASH as a substrate than peptidyl-
CoAs [31]. This reaction produces three undesired
species—both T domains loaded with CoASH, both T
domains loaded with N-acyl-L-Leu-CoA, and T1 loaded
with CoASH and T2 with N-acyl-L-Leu-CoA—as well as
the desired product—T1 loaded with N-acyl-L-Leu-
CoA and T2 loaded with CoASH. Although there are
four species, this does not complicate analysis of con-
densation products because only L-Asp is radiolabeled.
Therefore, only the two species loaded with CoASH on
their second Ts will be labeled in the autoaminoacyla-
tion reaction by A2. In turn, the Asp radiolabel will iden-
tify any N-acyl-Leu-Asp condensation product.
Analysis of the products released from T2 by LiOH hy-
drolysis and assayed as the acylated dipeptides estab-
lished that only N-acyl-D-Leu-L-Asp was formed, with
no N-acyl-L-Leu-L-Asp observed (Figure 2D). This find-
ing demonstrates that the acyl group appended to the
Leu1 amino group confers specificity for
DCL catalysis
by C2 of ArfA. Taken together with data from the previ-
ous experiments, these data suggest that epimerization
occurs after condensation to the upstream peptidyl-S-T
domain, but before condensation to the downstream
aminoacyl-S-T domain.
Identification of C Domains with Possible Dual
Activity for Peptidyl Condensation and
Epimerization
Previous bioinformatic analysis of C domain primary
sequences has led to the identification of two subcate-
gories, one of which directs the condensation of two L
amino acids, termed LCL catalysts for the L/L peptide
bond formed, and one that is found directly after a tradi-
tional epimerase domain that catalyzes condensation of
an upstream D-aminoacyl thioester with a downstream
L-aminoacyl thioester, termed DCL catalysts for the D/
L peptide bond formed [32, 33]. In this study, we find
a new, to our knowledge, subclass of C domains that fol-
low directly after T domains, as in the canonical NRPS
architecture without E domains present [34]; however,
the amino acid loaded onto that T domain appears as
a D isomer in the final product. As noted in Figure 3,
these C domains are found in four NRPS assembly lines
that have been annotated and sequenced: arthrofactin
[22], syringomycin [26], syringopeptin [27], and ramopla-
nin [35] synthetases. These C domains are proposed tohave dual catalytic roles for condensation and epimeri-
zation and to be DCL catalysts.
Sequence alignment of each individual C domain from
these four NRPS systems generates a phylogenetic tree
(Figure 3) that correctly predicts and clusters those C
domains that simply carry out condensation and those
that have dual roles for condensation and epimerization,
with three exceptions: C22 from syringopeptin synthe-
tase C, which is not predicted to have dual C/E activity
but is found following a D-diaminobutyrate (Dab) resi-
due, and C5 from syringopeptin synthetase A and C13
from syringopeptin synthetase C, which are predicted
to have dual C/E activity but are found following L-Val
and L-Ala residues, respectively (Figure 3). Sequence
alignment of the A domains and T domains from these
systems shows no such pattern or clustering of D amino
acids away from L amino acids when analyzing either
the amino acid activated by the A domain, the amino
acid one module upstream of the A domain (Figure S1;
see the Supplemental Data available with this article on-
line), or the amino acid loaded onto the T domain.
Analysis of the primary sequence of the proposed
dual C/E domains reveals that they contain an N-termi-
nal sequence that, to our knowledge, is not present in
the other sets of C domains. This sequence is com-
posed of w50 amino acids that terminate in a slightly
elongated His motif conforming to the sequence HHI/
LxxxxGD (Figure 4B). This elongated His motif is present
in addition to the conventional His motif (and arginine
Figure 3. Phylogenetic Analysis of C Domains from Arthrofactin,
Syringomycin, Syringopeptin, and Ramoplanin Synthetases
Those predicted to be conventional C domains are above the dot-
ted line, and those predicted to be dual C/E domains are below,
with exceptions noted by identification of the upstream donor sub-
strate. Clustering was performed in the Vector NTI program by us-
ing the neighbor-joining algorithm of Saitou and Nei [45]. Numbers
denote the distance from a common ancestor.
Chemistry & Biology
1194residue) found in all known C domains (Figure 4A). The
second His and terminal Asp in the His motif have
been shown to be critical for catalysis in both traditional
condensation domains and epimerase domains [15, 36].
Discussion
One feature of certain nonribosomal peptide synthe-
tases is that they incorporate D amino acid residues
Figure 4. Unique N-Terminal Sequence Present in C Domains with
Dual Condensation and Epimerization Activity
(A) Depiction of the conserved Arg, His, and Asp triad found in all E,
C, and dual C/E domains. The unique N-terminal sequence in C/E
domains is highlighted in gray with the secondary elongated His
motif identified.
(B) Sequence alignment of the N-terminal regions of C domains
from arthrofactin, syringomycin, syringopeptin, and ramoplanin
synthetases indicating a unique N-terminal sequence in proposed
dual C/E domains, which are grouped in the bottom half of the
alignment, starting with RamB C3. All C domains between ArfC
C8 and RamC C9 are conventional C domains. Alignments were
performed in the Vector NTI program suite. Residues highlighted
in black are highly conserved, and residues highlighted in gray
are moderately conserved. Arrows identify possible catalytic resi-
dues in the elongated His motif.into their peptide products. This is the case for the side-
rophore pyochelin, the antibiotics penicillin, vancomy-
cin, and tyrocidine, the biosurfactant surfactin, and the
immunosuppressant cyclosporin A [3, 37]. There have
been two characterized mechanisms by which D amino
acids can be incorporated into nonribosomal peptides.
The free D amino acid can be directly selected for acti-
vation by a corresponding A domain and loaded onto the
module responsible for its incorporation [3, 15, 18], as is
the case for D-Ala1 of cyclosporin synthetase [25]. How-
ever, the more conventional method entails epimeriza-
tion of proteinogenic and nonproteinogenic L amino
acids on their respective T domains during initiation
and elongation by embedded adjacent 50 kDa epimer-
ase domains, which act in cis on aminoacyl-S-Ppant
and peptidyl-S-Ppant substrates, respectively [3, 15,
18]. For example, the nonribosomal peptide tyrocidine
has two D-Phe residues at positions one and four in
the heptapeptide scaffold, and there are E domains in
module one and four of tyrocidine synthetase from the
gram-positive Bacillus brevis [32].
The lipoundecapeptide arthrofactin is an analogous
NRPS product in which 7 of the 11 amino acids are of
the D configuration. However, sequencing of the bio-
synthetic gene cluster from the gram-negative Pseudo-
monas sp. MIS38 revealed that there were no epimerase
domains present in the system [22]. In this study, we
have demonstrated that the first three A domains in ar-
throfactin synthetase responsible for incorporation of
D-Leu1, D-Asp2, and D-Thr3 are specific for activating
the L amino acid isomer. Michaelis-Menten kinetics re-
vealed that the catalytic specificity for activation of the
L amino acid substrate versus the D amino acid sub-
strate increases from 10-fold to over 1000-fold from
module 1 to module 3. This indicates that epimerization
to the D isomer must occur after activation and loading
of the L amino acid onto its cognate T domain.
Although it was initially postulated that external race-
mases must catalyze such a transformation [22], we
have shown that the epimerase activity is actually cryp-
tically embedded within the relevant modules of the syn-
thetase. Sequence alignment of arthrofactin synthetase
with three other systems that produce nonribosomal
peptides containing D amino acids in the absence of
epimerase domains (syringomycin, syringopeptin, and
ramoplanin synthetases) reveals that in addition to the
standard variety of condensation domain, these sys-
tems contain a novel, to our knowledge, condensation
domain that can be discerned by analysis of primary
amino acid sequence (Figure 3). These condensation
domains always lie directly downstream of the T domain
initially acylated with the amino acid that is epimerized
in the final product in all four systems [34]. Therefore,
we postulate that these C domains actually possess
dual activity for condensation and epimerization.
Of critical importance to the enzymology of NRPS as-
sembly lines is the proper timing and coordination of the
several processing steps that must occur on each
T-tethered intermediate as the peptide chain grows. In
addition to avoiding misinitiation of noncognate amino
acids by the A domain, the assembly line must avoid
stalling and premature hydrolytic termination of pep-
tidyl-S-T intermediates. C domains are presumed to
act as key gate keepers controlling the flow of
Dual Condensation/Epimerization Domains
1195elongating, covalently tethered intermediates in NRPSs.
When epimerization domains are present, an important
interplay must occur between the upstream and down-
stream condensation domains in order to prevent stall-
ing due to failed recognition of the correct isomer to be
elongated into the growing nonribosomal peptide prod-
uct [14, 19, 32, 38].
Generally, it appears that condensation domains al-
ways incorporate a downstream L amino acid monomer
into the growing peptide chain [32]. If the condensation
domain comes after an epimerization domain, then it is
a DCL catalyst, and it will only accept a carboxyterminal
D-aminoacyl thioester on the donor peptidyl chain for
condensation, as is the case for tyrocidine, gramicidin,
actinomycin, and pyochelin synthetases [14, 20, 32,
38]. Otherwise, condensation domains act as LCL cata-
lysts. This paradigm has the implication that unless epi-
merization domains are found in initiation modules, as is
the case for gramicidin (GrsA) and tyrocidine (TycA) syn-
thetases, which begin with A-T-E modules, epimeriza-
tion domains act on the peptidyl-S-T intermediates
rather than the aminoacyl-S-T monomers [16, 19, 32,
38]. Thus, E domains may serve as secondary gate
keepers controlling the kinetics of downstream chiral
condensation domains. No DCD condensation domains
have been reported.
The use of separate epimerization and chiral conden-
sation domains to control chain elongation in NRPSs
raises the interesting question of how seven modules
in arthrofactin synthetase, utilizing a single domain
with dual catalytic activity, are able to control the timing
of epimerizations and condensations to ensure that the
proper amino acid isomers are condensed and elon-
gated. Unlike conventional condensation domains that
follow epimerization domains with chiral specificity for
a single enantiomer, these dual C/E domains must inter-
act with both the L and D forms of the donor aminoacyl
groups they have to incorporate into the growing chain.
Analysis of epimerization of Leu1 and Asp2 by arthro-
factin synthetase reveals that epimerization precedes
condensation to a downstream amino acid, as shown
by the formation of uncondensed D amino acid, and
that subsequent condensation is DCL specific, just as
it is for the conventional subcategory of C domains
that follow standard epimerization domains. When us-
ing ArfA-C2A2T2 or ArfA-A2T2 as an initiation module
for condensation of Asp2 to Thr3, only the D-Asp-L-Thr
dipeptide is formed. However, when using ArfA-
C1A1T1 as an initiation module for condensation of
Leu1 to Asp2, both the D-Leu-L-Asp and L-Leu-L-Asp
dipeptides are formed. ArfA does not begin with a stan-
dard A-T initiation module, but rather contains a full C-
A-T organization like those normally found in elongation
modules [22]. This arrangement suggests that Leu1 is
acylated with a fatty acid before peptide elongation be-
gins. If this is the case, then perhaps the acyl group is
necessary to confer specificity for DCL catalysis by the
ArfA C2 domain. A similar case has been witnessed be-
fore in tyrocidine synthetase. Condensation of L-Phe
loaded onto TycB3-AT4E with L-Asn loaded onto
TycC1-C5AT5 yields a 2:1 mixture of the L-L and D-L di-
peptides, respectively. However, when the full natural
tetrapeptidyl substrate, D-Phe-L-Pro-L-Phe-L-Phe,
was loaded onto TycB3-AT4E, condensation with L-Asn yielded only the expected DCL product, D-Phe-L-
Pro-L-Phe-D-Phe-L-Asn [32, 38]. A similar switch to
full DCL chirality in ArfA module 1 was detected by using
3-hydroxybutyryl-L-Leu-S-T1 as a donor. The chiral se-
lectivity of a DCL peptide condensation domain may
be governed by the identity of the donor. Moreover,
this result has strong implications for the timing of acyl-
ation in the synthesis of arthrofactin. If the acyl chain is
necessary for chiral specificity of the downstream C do-
main, then Leu1 is most likely acylated before epimeri-
zation and condensation to Asp2. The acylation
reaction could be catalyzed by the first C domain of
ArfA based on homology with the quinoxaline biosyn-
thesis system in which functional crosstalk between
fatty acid synthases and NRPS was shown [39].
We have not yet dissected relative rates of epimeriza-
tion of L-aminoacyl-S-T domains, nor have we dissected
relative rates of subsequent stereoselective condensa-
tion of the D-aminoacyl-S-T-donor in the epimerization
equilibrium, much less absolute rates. Such studies
will require rapid quench, single turnover studies.
In addition to calibrating the timing of epimerization
and chirality of condensation, this study shows that
the epimerization reaction does not take place unless
the downstream T domain is loaded with the amino
acid to which the epimerized product is subsequently
condensed. Epimerization of Leu1 by ArfA-C2 does not
occur unless Asp2 is loaded onto ArfA-T2, and epimeri-
zation of Asp2 by ArfB-C3 does not occur unless Thr3 is
loaded onto ArfB-T3. Such a gating mechanism implies
that these dual C/E domains assume three conforma-
tional states that are populated dynamically depending
on the availability of the upstream donor and down-
stream acceptor substrates (Figure 5A). First, there ex-
ists a resting C/E state that is capable of interacting
with both the upstream and downstream T domains
loaded with their cognate L amino acids, but is incom-
petent for either condensation or epimerization. Once
the upstream peptidyl-S-Ppant and downstream ami-
noacyl-S-Ppant are present and interacting with the
dual C/E domain, a C/E0 conformation arises in which
the domain becomes competent for epimerization of
the upstream aminoacyl thioester. Finally, in the pres-
ence of the upstream D-aminoacyl-S-T, a C/E0 0 confor-
mation develops that is now condensation competent,
resulting in elongation of the peptidyl chain with D/L chi-
rality. Mechanistic studies remain to be conducted, but
it is likely that removal of the Ca-H of the donor L-amino-
acyl-S-Tn-1 occurs only when the downstream acceptor
substrate is presented, perhaps to drive a conforma-
tional change in the C domain (Figure 5B).
It is of interest to note that in the phylogenetic tree of
C domains from arthrofactin, syringomycin, syringo-
peptin, and ramoplanin synthetases, the C domains
that lie downstream of T domains that are responsible
for incorporating 2,3-dehydroaminobutyric acid (Dhb)
cluster with the dual C/E domains (Figure 3), even
though these are not chiral residues. Evaluation of the
A domains that supposedly activate these amino acids
show that they cluster with those A domains responsi-
ble for activating b-branched amino acids, like L-Val,
L-Thr, and L-Ile (Figure S1). Furthermore, radioactive
feeding experiments done in Pseudomonas syringae
demonstrate that these Dhb moieties are derived from
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domains could also function as dual condensation/de-
hydration domains with or without prior epimerization.
It will be of interest to see if a D-threonyl-S-T gets selec-
tively dehydrated and then condensed.
In gram-positive NRPS assembly lines, it has been
noted that E domains and C domains are homologous
and that E domains may have evolved from C domains
by domain duplication [41] followed by divergent evolu-
tion. E domains in the gram-positive assembly lines are
often at the C termini of subunits and may pair up with
the downstream C domains for specificity. This snap-
shot of the gram-negative NRPS assembly lines may re-
veal epimerization-competent condensation domains
before C to E domain duplications arose. Evidence for
a similar paradigm can be found in the VibF subunit of
vibriobactin synthetase. Whereas cyclization (Cy) do-
mains normally catalyze both heterocyclization and
condensation, VibF contains tandem Cy domains, with
one only capable of catalyzing condensation and the
other only capable a catalyzing heterocyclization [42].
Figure 5. Proposed Conformational State and Mechanism for the
Dual Condensation and Epimerization Activity of C/E Domains
(A) Scheme depicting the three conformational states of dual C/E
domains. When the resting C/E state interacts with the upstream
peptidyl-S-Ppant donor and the downstream aminoacyl-S-Ppant
acceptor, an epimerization-competent C/E0 state arises, which sub-
sequently leads to a condensation-competent C/E$ conformation
after epimerization. It is unknown whether the epimerization reac-
tion is reversible.
(B) Chemical schematic for epimerization of the donor aminoacyl/
peptidyl-S-T domain to the D isomer utilized for condensation with
the downstream L-aminoacyl-S-T domain.One eventual goal of NRPS research is the combina-
torial swapping of modules into engineered synthetases
to produce novel biologically active natural products. If
one wishes to incorporate D amino acids into these new
compounds utilizing standard epimerization domains, it
will also be necessary to swap in a corresponding DCL
chiral condensation domain. Furthermore, it has been
demonstrated that T domains upstream of epimeri-
zation domains show signature differences from
standard T domains in the residues surrounding the
phosphopantetheinylated conserved Ser, most notably
adopting a DSI sequence in the CoreT motif rather than
the standard HSL sequence [19]. Therefore, in con-
structing chemical libraries by using engineered nonri-
bosomal peptide synthetases, one would have to
swap in at least three unique domains (TE-E-CE) for
each D amino acid incorporated. The novel, to our
knowledge, dual C/E domains described in this study
should serve as usefully economic alternatives for in-
corporating D amino acids because they integrate the
catalytic functions of two domains into one, and they
lie downstream of what appears to be the standard va-
riety of T domain conforming to the HSL sequence.
Significance
D amino acid residues are key constituents of many
bioactive nonribosomal peptides. Free D amino acid
levels are low in microbial NRP producers. Typically,
L amino acid monomers are activated and epimerized
on the multimodular NRPS assembly lines. While dis-
tinct 50 kDa epimerase (E) domains have previously
been found in NRPS modules of several strains
(mostly gram-positive), there are no comparable E do-
mains in NRPS assembly lines from multiple gram-
negative Pseudomonas strains. We demonstrate that
for the pseudomonal arthrofactin synthetase mod-
ules, which activate L amino acids and epimerize
them as covalently tethered pantetheinyl thioesters,
the condensation (C) domains have both peptide
bond-forming condensation and upstream amino-
acyl-S-pantetheinyl donor epimerization activities.
Dual C/E condensation domains may have been pre-
cursors to separate E domains and offer promise as
portable domains for the generation of D amino acid
residues in combinatorial biosynthesis.
Experimental Procedures
Materials and General Methods
Standard recombinant DNA, molecular cloning, and microbiological
procedures were performed as described [43]. Competent Top10
and BL21 (DE3) E. coli strains were purchased from Invitrogen. Oli-
gonucleotide primers were purchased from Integrated DNA Tech-
nologies. Restriction enzymes and T4 DNA ligase were purchased
from New England Biolabs. Herculase DNA polymerase was pur-
chased from Stratagene. Plasmids pET28b and pET37b were pur-
chased from Novagen. DNA sequencing to verify PCR fidelity was
performed on double-stranded DNA by the Molecular Biology
Core Facilities of the Dana Farber Cancer Institute (Boston, MA).
Plasmid DNA preparation was performed by using the Qiaprep kit
from Qiagen, PCR cleanup was carried out by using the Qiaquick
kit from Qiagen, and gel extraction of DNA fragments as well as re-
striction endonuclease cleanup were done by using the GFX kit from
GE Healthcare. Ni-NTA Superflow resin was from Qiagen. FPLC pu-
rification of proteins was performed by using a HiLoad 26/60
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with a UPC-900 detector and a Frac-950 fraction collector (GE
Healthcare) with a running buffer of 20 mM Tris (pH 8.0), 50 mM
NaCl, 2 mM MgCl2, and 1 mM DTT. SDS-PAGE gels were from Bio-
Rad. Protein samples were concentrated by using a 10KMWCO
Amicon Ultra device from Millipore, and final protein concentrations
were calculated by using the protein’s absorbance at 280 nm and
the predicted molar extinction coefficient.
HOBt, HBTU, Pybop, Boc- and Fmoc-protected amino acids, and
2-chlorotrityl resin were purchased from NovaBiochem. Preparative
HPLC was performed on a Beckman Coulter System Gold instru-
ment with a Vydac Proteins and Peptides C18 column (10 mm,
22 3 250 mm). LCMS identification was carried out on a Shimadzu
LCMS-QP8000a equipped with two LC-10ADVP liquid chromatog-
raphy pump modules, a SPD-10AVVP UV-vis detector, a SIL-
10ADVP autosampler module, and a Vydac C18 Mass Spec column
(5 mM, 2.1 3 250 mm).
Radiolabeled L-[14C]Leu (331 mCi/mmol) was purchased from
Perkin-Elmer Life Sciences; D-[14C]Leu (55 mCi/mmol), [32P]PPi, L-
[14C]Asp (208 mCi/mmol), and D-[14C]Asp (55 mCi/mmol) were pur-
chased from American Radiolabeled Chemicals, Inc. (ARC), and L-
[14C]Thr (184.2 mCi/mmol) was purchased from Sigma. Purified Ba-
cillus subtilis phosphopantethienyl transferase Sfp [28, 29] was
provided by M. Fischbach. Purified Bacillus brevis TycF [30] was
provided by E. Yeh. BioMax centrifugal filters were purchased
from Millipore. Chiral silica TLC plates from Aldrich were exposed
to a BAS-IIIs image plate for approximately 24 hr and subsequently
read by a Typhoon 9400 variable mode imager (GE Healthcare) fol-
lowed by analysis with ImageQuant Software. Radio-HPLC was per-
formed by using a Beckman Coulter System Gold instrument
equipped with a b-Ram module 3 radioisotope detector (IN/US
Systems).
All other chemicals and HPLC solvents were purchased from
Sigma-Aldrich and were used without further purification.
Cloning of Arf Genes, Overproduction,
and Purification of Arf Proteins
All constructs were obtained from PCR amplification of a l5 clone of
the arthrofactin gene cluster, which was a gift from Dr. Masaaki
Morikawa, Osaka, Japan [22]. This template was amplified by using
the following oligonucleotide primers (italics: modified sequences,
underlined: restriction site): ArfA-C1A1T1: 5
0-GGAATTCCATATGCC
GCCTATTTCTGCCCCTGCGG-30 and 50-CGGAATTCATCAATGGGT
GCAATCGGCGGCGATGCG-30; ArfA-C1A1T1C2A2T2: 50-GGAATTC
CATATGCCGCCTATTTCTGCCCCTGCGG-30 and 50-CCGCTCGAG
CCGGCGTTTGCGATTGAGGCTC-30; ArfA-C2A2T2: 50-GGAATTC
CATATGATCACTCCGGCAATGCTGCCGCTG-30 and 50-CCGCTCG
AGCCGGCGTTTGCGATTGAGGCTC-30; ArfA-A2T2: 50-GGAATTC
CATATGGAGGTCGATTGTCCGCTGGAC-30 and 50-TGCCC
AAGCTTCTACTAGAGCCGGCGTTTGCGATTGAG-30; ArfB-C3: 50-
GGAATTCCATATGCATTTCAGCGAACTGATGGC-30 and 50-CCG
CTCGAGGTAGCTCAGCGTCTGCTCTTCGAAC-30; ArfB-C3A3T3: 50-
GGAATTCCATATGCATTTCAGCGAACTGATGGC-30 and 50-CCG
CTCGAGGTAAATATCCTGCACATTGCCGAC-30. ArfA-C1A1T1C2
A2T2, ArfA-C2A2T2, ArfB-C3, and ArfB-C3A3T3 PCR products were di-
gested with NdeI/XhoI and ligated into similarly digested pET37b to
create C-terminal His8-tagged constructs, the ArfA-C1A1T1 PCR
product was digested with NdeI/EcoRI and ligated into similarly di-
gested pET28b to create an N-terminal His6-tagged construct, and
the ArfA-A2T2 PCR product was digested with NdeI/HindIII and li-
gated into similarly digested pET28b to create an N-terminal His6-
tagged construct.
The described expression plasmids were transformed into E. coli
BL21 (DE3)-competent cells. The four constructs larger than two
domains were grown at 15ºC, and the other two constructs were
grown at 25ºC in Luria-Bertani media supplemented with 5 mM
MgCl2 and 40 mg/ml kanamycin to an OD600 of 0.5–0.8 when the cul-
ture was induced with 100 mM IPTG and then grown for an additional
12–36 hr. The cells were harvested by centrifugation at 4000 3 g for
16 min and stored as pellets at 280ºC until further use. Cell pellets
from 4 L of culture were thawed and resuspended in 35 ml buffer (25
mM Tris [pH 8.0], 500 mM NaCl) and then lysed with two passes on
an Emulsiflex-C5 cell disruptor (Avestin). The lysate was cleared by
ultracentrifugation at 95000 3 g for 35 min and then transferred to700 ml Ni-NTA resin for incubation at 4ºC for 2 hr. The resin was
then transferred to a column, and the protein was eluted with an im-
idazole gradient by using steps of 10 ml of 0 and 5 mM imidazole
and then 5 ml of 25 and 200 mM imidazole mixed into lysis buffer.
After running an SDS-PAGE gel to verify which fractions contained
the protein, the 25 and 200 mM imidazole fractions were dialyzed
overnight against 20 mM Tris (pH 8.0), 50 mM NaCl, 2 mM MgCl2,
1 mM DTT, and 10% glycerol. The dialyzed protein was then
concentrated to 1.5 ml and subjected to gel filtration purification.
After confirming which fractions contained the protein of interest
by using SDS-PAGE, the resulting fractions were concentrated,
supplemented with 10% glycerol, flash frozen in liquid nitrogen,
and stored at 280ºC.
Mutagenesis and Purification of ArfA-C1A1T1C2A2T2 S2079A
The gene for the full-length ArfA second T domain knockout mutant
was constructed via the splicing by overlap extension (SOE) method
[44] by using the pET37b ArfA-C1A1T1C2A2T2 plasmid as template.
In the first round of PCR amplification, the 50 fragment of the mutant
was amplified by using the primers (underlined: restriction site,
bold: mutation) 50-CCTGCCATTCGGCCTGCAGGAAGTGCAGGGC
GACGG-30 and 50-CACCGCCAGCAACGCATGCCCACCGAG-30,
and the 30 fragment of the mutant was amplified by using the pri-
mers 50-CTCGGTGGGCATGCGTTGCTGGCGGTG-30 and 50-
CTCGAATCTCGAGGGTGGCGTTGAACGTGATCAG-30. After PCR
purification, the two fragments were mixed together and further am-
plified by using the forward first primer from the 50 fragment and the
reverse second primer from the 30 fragment. The final PCR product
was digested with SbfI/XhoI and ligated into a similarly digested
pET37b ArfA-C1A1T1C2A2T2 plasmid. The mutant ArfA enzyme was
purified as described for the wild-type enzyme.
ATP-PPi Exchange Assay for ArfA
Domain Substrate Specificity
Reactions (100 ml) contained 75 mM Tris (pH 7.5), 10 mM MgCl2, 5
mM DTT, 5 mM ATP, 1 mM sodium [32P]pyrophosphate (0.18 mCi),
100 mg/ml BSA with 0.05 or 0.1 mM enzyme or only 1 mM enzyme,
and substrate amino acid concentrations ranging from 0.05 to 17
mM. Reactions were incubated at room temperature for either 5 or
10 min and were quenched by the addition of 500 ml 1.6% (w/v) ac-
tivated charcoal, 200 mM tetrasodium pyrophosphate, and 3.5%
perchloric acid in water. The charcoal was pelleted by centrifugation
and washed twice with 500 ml 200 mM tetrasodium pyrophosphate
and 3.5% perchloric acid in water. The radioactivity bound to the
charcoal was then measured by liquid scintillation counting. Note
that enzyme concentrations and reaction times were chosen such
that ATP-PPi exchange remained under 15% of equilibrium levels.
Analysis of Phosphopantetheinylation
of Apo T Domain Constructs
Reactions (20 ml) to determine whether the T domains were func-
tional for phosphopantetheinylation contained 50 mM Tris (pH
7.5), 5 mM MgCl2, 1 mM DTT, 100 mM CoASH, 10 mM A domain-con-
taining enzyme, and 3 mM Sfp. After incubation at room temperature
for 1 hr, amino acid loading onto the T domain was initiated with 300
mM 14C radiolabeled substrate and 5 mM ATP. At various time points
ranging from 2 s to 10 min, reactions were quenched into 100 ml 10%
TCA with 5 ml 40 mg/ml BSA. Samples were centrifuged and washed
twice with 200 ml 10% TCA, and the protein pellet containing cova-
lently bound radiolabeled amino acid was resolubilized in 200 ml for-
mic acid and quantified by liquid scintillation counting. Alternatively,
the reactions were quenched into 20 ml of 23 SDS-PAGE running
buffer (without reducing agent), then loaded and run on a 5% poly-
acrylamide gel. The gel was then dried down, exposed to a phos-
phorimager plate overnight, and then scanned to see if
radioactivity was bound to the protein band.
Synthesis of Dipeptide Standards: L-Leu-L-Asp,
D-Leu-L-Asp, L-Asp-L-Thr, and D-Asp-L-Thr
0.33 mmol H-Asp(OtBu)-2-ClTrt resin or 0.33 mmol H-Thr(OtBu)-2-
ClTrt resin was swelled in DMF then reacted with 3 equivalents of
Boc-D-Leu-OH/Boc-L-Leu-OH or Boc-D-Asp(OtBu)-OH/Boc-L-As-
p(OtBu)-OH, respectively, 3 equivalents of HBTU, 1 equivalent of
HOBt, and 12 equivalents of DIEA dissolved in 5 ml DMF while
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washed three times with 3 ml DMF and three times with 3 ml
CH2Cl2, followed by deprotection and cleavage from the resin over-
night by using 2 ml 90/5/5 TFA/H20/TIS. The TFA was rotovapped
off, and the product was redissolved in H2O and purified by prepar-
ative HPLC with a gradient of 0%–25% acetonitrile over 25 min start-
ing in 0.1% TFA in H20. Product peaks were identified by LCMS and
lyophilized to dryness: L-Leu-L-Asp 247.13 [(M + H+)] calculated,
246.90 observed; D-Leu-L-Asp 247.13 [(M + H+)] calculated, 246.90
observed; L-Asp-L-Thr 235.09 [(M + H+)] calculated, 234.80 ob-
served; D-Asp-L-Thr 235.09 [(M + H+)] calculated, 234.85 observed.
Synthesis of t-Butyl-R-3-Hydroxybutyrate
R-3-hydroxybutyrate methyl ester (16.93 mmol) was dissolved in
28.22 ml CH2Cl2 and sealed in an airtight vial to which 295 ml
H3PO4 (made by adding 0.4 g P2O5 to 1.1 ml 86% H3PO4 to remove
the water), 703 ml BF3$Et2O, and 14.2 ml isobutylene was added in
respective order. The reaction was mixed at 275ºC for 2.5 hr and
then overnight at room temperature. The resulting reaction mixture
was dissolved in 100 ml ethyl acetate, washed twice with 50 ml sat-
urated sodium bicarbonate and once with 50 ml NaCl brine. The
product was redissolved in a minimal amount of CH2Cl2 after the
ethyl acetate was removed by rotovap and then subjected to purifi-
cation over a silica gel column. A wash of 300 ml 5:1 hexanes:CH2Cl2
removed what appeared to be polymer formed in the reaction. The
t-butyl-protected product eluted from the column in a subsequent
400 ml wash of 7:1 hexanes:ethyl acetate as determined by TLC.
Product was rotovapped to dryness.
Deprotection of the methyl ester was performed by dissolving
2.87 mmol t-butyl-R-3-hydroxybutyrate methyl ester with 2 equiva-
lents of LiOH in 10 ml 1:1 H2O:MeOH and reacting it at room temper-
ature for 1.5 hr. The solution was then acidified to pH 1.5 with
ice-cold HCl and quickly extracted three times with 7 ml ethyl ace-
tate. The product was rotovapped to dryness and confirmed by
LCMS: t-butyl-R-3-hydroxybutyrate 159.10 [(M 2 H)2] calculated,
158.95 observed.
Synthesis of N-Acyl-Dipeptide Standards:
N-Acyl-L-Leu-L-Asp and N-Acyl-D-Leu-L-Asp
0.2 mmol H-Asp(OtBu)-2-ClTrt resin was swelled in DMF then re-
acted with 3 equivalents of either Fmoc-D-Leu-OH or Fmoc-
L-Leu-OH, 3 equivalents of HBTU, 1 equivalent of HOBt, and 12
equivalents of DIEA dissolved in 3 ml DMF while shaking at room
temperature for 3 hr. Afterwards, the resin was washed three times
with 3 ml DMF and three times with 3 ml CH2Cl2, followed by depro-
tection with 2 3 3 ml 20% piperidine for 10–15 min. After washing
three times with 3 ml DMF and three times with 3 ml CH2Cl2, the sec-
ond coupling reaction was performed by the addition of 1.5 equiva-
lents of t-butyl-R-3-hydroxybutyrate, 1.5 equivalents of HBTU, 1
equivalent of HOBt, and 6 equivalents of DIEA dissolved in 1.5 ml
DMF while shaking at room temperature for 2.5 hr. After washing
three times with 3 ml DMF and three times with 3 ml CH2Cl2, the
product was deprotected and cleaved from the resin for 3 hr by
using 3 ml 90/5/5 TFA/H20/TIS. The TFA was rotovapped off, and
the product was redissolved in H2O and purified by preparative
HPLC with a gradient of 0%–100% acetonitrile over 40 min starting
in 0.1% TFA in H20. Product peaks were identified by LCMS and
lyophilized to dryness: N-acyl-L-Leu-L-Asp 331.15 [(M 2 H)2] cal-
culated, 331.10 observed; N-acyl-D-Leu-L-Asp 331.15 [(M 2 H)2]
calculated, 331.05 observed.
Synthesis of N-Acyl-L-Leu-CoA Substrate
0.417 mmol H-Leu-2-ClTrt resin was swelled in DMF then reacted
with 1.5 equivalents of t-butyl-R-3-hydroxybutyrate, 1.5 equivalents
of HBTU, 1 equivalent of HOBt, and 6 equivalents of DIEA dissolved
in 3.125 ml DMF while shaking at room temperature for 2.5 hr. After
washing three times with 3 ml DMF and three times with 3 ml
CH2Cl2, the product was cleaved from the resin without deprotec-
tion with 3 ml 1:1:3 AcOH:TFE:CH2Cl2 while shaking at room temper-
ature for 2 hr. The CH2Cl2 was rotovapped off, and the product was
redissolved in H2O and purified by preparative HPLC with a gradient
of 0%–100% acetonitrile over 40 min starting in 0.1% TFA in H2O.
The product peak was identified by LCMS and lyophilized todryness: t-butyl-R-3-hydroxybutyryl-L-Leu 272.18 [(M2 H)2] calcu-
lated, 272.15 observed.
73.1 mmol N-acyl-L-Leu was reacted with 2 equivalents of CoASH,
4 equivalents of Pybop, and 8 equivalents of DIEA dissolved in 1.5
ml 1:1 THF:H2O while stirring at room temperature for 3 hr. The re-
action was then purified by direct injection onto the preparative
HPLC with a 0%–100% acetonitrile gradient over 40 min starting
in 0.1% TFA in H2O. The product peak was identified and lyophilized
to dryness: t-butyl-R-3-hydroxybutyryl-L-Leu-CoA 1021.30 [(M 2
H)2] calculated, 1021.00 observed. Deprotection was achieved by
reacting with 1 ml 95/5/5 TFA/H2O/TIS for 3 hr at room temperature.
The solution was then diluted to 5 ml with H2O and injected onto the
preparative HPLC with a gradient of 0%–100% acetonitrile over 40
min starting in 0.1% TFA in H2O. The product peak was identified
and then lyophilized to dryness: N-acyl-L-Leu-CoA 965.25 [(M 2
H)2] calculated, 964.90 observed.
Analysis of Epimerization Activity
on Aminoacyl-S-T Substrates
10 mM of each enzyme included in the 120 ml reaction was primed by
incubation with 50 mM Tris (ArfA C2 containing reactions) or HEPES
(ArfB C3 containing reactions) (pH 7.5), 5 mM MgCl2, 100 mM
CoASH, and 3 mM Sfp at room temperature for 1 hr. Amino acid load-
ing, epimerization, and condensation were then assayed by initia-
tion with 37.5 mM Tris or HEPES (pH 7.5), 5 mM ATP, 100–500 mM
14C radiolabeled amino acid (depending on how concentrated the
radioactive stock was) and 500 mM cold partner amino acid (if in-
cluded). After 10 min, reactions were transferred to BioMax centrif-
ugal filters and washed 43 500 ml with 50 mM Tris or HEPES (pH 7.5)
with centrifugation between each wash. 50 mM of the external thio-
esterase TycF was then added to the reaction, which was at a total
volume of 25 ml. Cleavage of the T domain bound products pro-
ceeded at room temperature for 1 hr, and then the products were
filtered out with three 100 ml washes with H2O. After lyophilization,
the products were redissolved in 10 ml 50/50 MeOH/H2O. The reac-
tions containing ArfA C2 to assay Leu1 were analyzed by using chiral
silica TLC with a developing buffer of 200/50/25/25 ACN/AcOH/
MeOH/H2O followed by phosphorimaging. The reactions containing
ArfB C1 to assay Asp2 were analyzed by using chiral HPLC analysis
on a Phenomenex 250 3 4.6 mm 3126 Chirex column, with 95%
2 mM copper sulfate in 5% isopropanol, isocratic, monitoring 14C
radioactive counts and absorbance at 220 nm.
Analysis of Epimerization Activity
on N-Acyl-L-Leu-Peptidyl-S-T Substrate
10 mM ArfA C1A1T1C2A2T2 included in the 300 ml reaction was primed
by incubation with 50 mM Tris (pH 7.5), 5 mM MgCl2, 140 mM N-acyl-
L-Leu-CoA, 60 mM CoASH, and 3 mM Sfp at room temperature for 1
hr. Substrate loading, epimerization, and condensation were then
assayed by initiation with 37.5 mM Tris (pH 7.5), 5 mM ATP, and
100 mM L-[14C]Asp. After 10 min, the reaction was quenched with
1.2 ml 10% TCA, pelleted by centrifugation, and washed three times
with 100 ml with 10% TCA. Cleavage of the T domain bound prod-
ucts were performed by resuspending in 100 ml 0.1 M LiOH and
heating at 60ºC for 15 min. The reaction was then quenched by acid-
ifying with 20 ml 50% TCA and centrifuged to pellet the protein. The
supernatant containing the released products was analyzed by
HPLC on a Vydac 250 3 4.6 mm C18 small pore column, with
a 0%–50% acetonitrile gradient over 25 min starting in 0.1% TFA
in H2O, monitoring
14C radioactive counts and absorbance at
220 nm.
Supplemental Data
Supplemental Data including phylogenetic analysis of A domains
from arthrofactin, syringomycin, syringopeptin, and ramoplanin syn-
thetases are available at http://www.chembiol.com/cgi/content/full/
12/11/1189/DC1/.
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